Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Medical Hypotheses

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.mehy.2018.02.036PMID 29602462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

  2018cited by this paper
• Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

  2017cited by this paper
• Role of NLRP3 Inflammasomes in Atherosclerosis

  2017cited by this paper
• Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

  2017cited by this paper
• Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

  2017cited by this paper
• Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

  2017cited by this paper
• Triple Therapy for Atrial Fibrillation after PCI.

  2017cited by this paper
• Cross-talk between macrophages and atrial myocytes in atrial fibrillation

  2016cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

  2016cited by this paper
• Antiplatelet therapy: Vorapaxar in diabetes and MI

  2015cited by this paper
• Targeted sequencing in candidate genes for atrial fibrillation: the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study.

  2014cited by this paper
• Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous

  2014cited by this paper
• Endothelial (dys)function in lone atrial fibrillation.

  2014cited by this paper
• Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association

  2014cited by this paper
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

  2014cited by this paper
• Low-dose colchicine for secondary prevention of cardiovascular disease.

  2013cited by this paper
• Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data.

  2013cited by this paper
• Assessment of Interleukin‐1 Gene Cluster Polymorphisms in Lone Atrial Fibrillation: New Insight into the Role of Inflammation in Atrial Fibrillation

  2013cited by this paper
• Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial

  2012cited by this paper
• C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

  2010cited by this paper
• Triple antithrombotic management after stent implantation: when and how?

  2009cited by this paper
• C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study

  2008cited by this paper
• Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation

  2008cited by this paper
• Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study.

  2008cited by this paper
• Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention

  2007cited by this paper
• Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.

  2007cited by this paper
• Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.

  2007cited by this paper
• Genetic factors for lone atrial fibrillation.

  2007cited by this paper
• Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

  2007cited by this paper
• Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice.

  2006cited by this paper
• Is atrial fibrillation an inflammatory disorder?

  2006cited by this paper
• Inflammation in the genesis and perpetuation of atrial fibrillation.

  2005cited by this paper
• Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice.

  2005cited by this paper
• Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics

  2004cited by this paper
• Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs

  2004cited by this paper
• C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany

  2004cited by this paper
• Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation.

  2004cited by this paper
• Atrial fibrillation following methylprednisolone pulse therapy

  2004cited by this paper
• Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation

  2004cited by this paper
• Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation.

  2004cited by this paper
• The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases:

  2004cited by this paper
• Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion.

  2004cited by this paper
• Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis.

  2003cited by this paper
• The −174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation. Is Atrial Fibrillation an Inflammatory Complication?

  2003cited by this paper
• Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation.

  2003cited by this paper
• Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials

  2003cited by this paper
• Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion.

  2003cited by this paper
• Lack of Interleukin-1&bgr; Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice

  2003cited by this paper
• Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study.

  2003cited by this paper
• Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

  2003cited by this paper
• The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.

  2003cited by this paper
• A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation

  2002cited by this paper
• Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study

  2002cited by this paper
• Platelets in atherothrombosis

  2002cited by this paper
• Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function.

  2001cited by this paper
• Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

  2001cited by this paper
• Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery.

  2000cited by this paper
• Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation.

  2000cited by this paper
• The New England Journal

  2000cited by this paper
• C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

  1999cited by this paper
• Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

  1999cited by this paper
• Atherosclerosis is an Inflammatory Disease

  1998cited by this paper
• Pulmonary Effects of Methylprednisolone in Patients Undergoing Coronary Artery Bypass Grafting and Early Tracheal Extubation

  1998cited by this paper
• Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.

  1997cited by this paper
• Histological substrate of atrial biopsies in patients with lone atrial fibrillation.

  1997cited by this paper
• Cytokines, platelet production and hemostasis.

  1997cited by this paper
• Cytokine–Induced Alteration of Platelet and Hemostatic Function

  1996cited by this paper
• Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor.

  1996cited by this paper
• C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

  1993cited by this paper
• Atrial fibrillation following pulse methylprednisolone therapy in an adult.

  1993cited by this paper
• Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control.

  1990cited by this paper
• Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells

  1984cited by this paper

• Exploring the potential link between human papillomavirus infection and coronary artery disease: a review of shared pathways and mechanisms

  2025cites this paper
• HPV infection as a risk factor for atherosclerosis: A connecting hypothesis.

  2020cites this paper
• Role of inflammatory signaling in atrial fibrillation.

  2019cites this paper
• A post-surgical adjunctive hypoxic therapy for myocardial infarction: Initiate endogenous cardiomyocyte proliferation in adults.

  2019cites this paper
• A Vascular Thrombus Therapy Method Based on Magnetic‐Induced Vibration

  2019cites this paper